Pharmaceutical companies have become cautious with regard to mergers and acquisitions (M&As) as business environment remains challenging due to pricing pressure and regulatory interventions in key markets—the US and India. This has led to a decline in volume as well as value of M&A deals in the pharma sector in the current year.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
